| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
UGT1A1 Gene Polymorphism (TA Repeat) : 1015360
Test CodeUGT1AQ or 1015360
Alias/See Also
Irinotecan Toxicity, Colorectal Cancer (CRC), Irinotecan Metabolism, Gilbert's Syndrome, UPD-glucuronosyltransferase 1A1 (UGT1A1); TA7; 28 allele
CPT Codes
81350
Instructions
Lavender (EDTA), green (no gel) (sodium or lithium heparin), or royal blue (EDTA).
Transport Container
Transport 5 mL whole blood, (Min: 3 mL).
Transport Temperature
Refrigerated.
Specimen Stability
Ambient: 8 days; Refrigerated: 8 days; Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis, Clotted blood, Received frozen.
Methodology
Fluorescent Polymerase Chain Reaction
Setup Schedule
Monday & Thursday
Report Available
6-10 days (From receipt at performing laboratory)
Limitations
Individuals with two copies of TA7 have a higher risk of side effects such as neutropenia and diarrhea when treated with irinotecan. This assay does not detect other variants or mutations in the UGT1A1 gene which may impair irinotecan metabolism. Neither does it examine other genetic or non-genetic modifiers of irinotecan metabolism.
This test was developed and its performance characteristics have been determined by Quest Diagnostics. Performance characteristics refer to the analytical performance of the test.
This test was developed and its performance characteristics have been determined by Quest Diagnostics. Performance characteristics refer to the analytical performance of the test.
Reference Range
By report.
Clinical Significance
This assay is intended for selection of colorectal cancer patients who would benefit most and experience the least toxicity from 5-fu, oxaliplatin and irinotecan chemotherapy by determining the individual patient genotypes to guide chemotherapy choices in advanced stage colorectal cancer.
Performing Laboratory
Quest Diagnostics
